Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Plos One|April 11, 2020
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis BPatrick Marcellin, Qing Xie, Seung Woon Paik, et al.
Gastroenterologie Clinique Et Biologique|April 9, 2002
[Registry of liver biopsies from hepatitis C infected patients in the Alpes-Maritimes (France). Results from the first 2 years]Eugènia Mariné-Barjoan, Eric Fontas, Christian Pradier, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 21, 2013
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisionsAlessandra Mangia, Tivadar Bányai, Giuseppe De Bartolomeo, et al.
Gastroenterology|October 13, 2006
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirinJean-Pierre Bronowicki, Denis Ouzan, Tarik Asselah, et al.
European Journal of Gastroenterology & Hepatology|December 23, 2017
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO studyDominique Roulot, Vincent Thibault, Claire Laforest, et al.
Antiviral Therapy|July 22, 2017
Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohortPhilippe Halfon, Caroline Scholtès, Jacques Izopet, et al.
The American Journal of Gastroenterology|March 18, 2006
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca studyPhilippe Halfon, Marc Bourliere, Romaric Deydier, et al.
Digestive Diseases and Sciences|January 29, 2016
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in FrancePatrick Marcellin, Fabien Zoulim, Christophe Hézode, et al.
Digestive Diseases and Sciences|April 19, 2020
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in FranceDenis Ouzan, Dominique Larrey, Dominique Guyader, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohortsAlessandra Mangia, Scott Milligan, Mandana Khalili, et al.
Pageof 7